Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation
It is always desirable to have more options in this space, KRAS G12c mutated NSCLC lung patients. A median duration of response above 8 months is rather exciting in this setting. Detection of such patients who may be candidates for such therapy is of critical importance.